If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Australia Approves WinRho SDF For Blood-Type Incompatibility Between Mother And Unborn Child TORONTO, ON and WINNIPEG, MB -- July 13, 2000 -- Cangene reports that its WinRho SDF™ has received Australian regulatory approval for treating hemolytic disease of the newborn (HDN), a severe blood-type incompatibility between a pregnant woman and her unborn child. A true Canadian success story, proper use of WinRho prevents deaths due to HDN. The product will be distributed in Australia by CSL Ltd., that country's largest pharmaceutical company. CSL manufactures a similar product but is unable to meet the growing demand. "This is a sizable new market for us, and with a strong distributor like CSL, I expect WinRho to do well. CSL has already been selling WinRho in the smaller New Zealand market since it was approved in late 1999," said John Langstaff, Cangene's president and CEO. Cangene and CSL have a five-year agreement --details have not been disclosed, but CSL has guaranteed certain minimum quantities that increase each year of the contract. WinRho SDF®, Cangene's first commercial hyperimmune product, is a purified antibody that reacts with a certain type of red blood cell (Rh+ cells). In addition to its use in preventing hemolytic disease of the newborn, the drug is also licensed to treat ITP (immune thrombocytopenic purpura; an immune-mediated clotting deficiency) in the U.S., Canada and Israel. WinRho is purified from specially collected human plasma and manufactured using an industry-leading combination of solvent-detergent and nanofiltration for virus inactivation. Cangene has sold the drug in more than twenty countries worldwide.
|
